BR112019015453A2 - Agentes ligantes - Google Patents
Agentes ligantes Download PDFInfo
- Publication number
- BR112019015453A2 BR112019015453A2 BR112019015453-1A BR112019015453A BR112019015453A2 BR 112019015453 A2 BR112019015453 A2 BR 112019015453A2 BR 112019015453 A BR112019015453 A BR 112019015453A BR 112019015453 A2 BR112019015453 A2 BR 112019015453A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody molecules
- gitr
- specifically bind
- binding agents
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
a invenção refere-se a moléculas de anticorpo e frações de ligação ao antígeno da mesma que se ligam especificamente ao receptor de tnf induzido por glucocorticoide (gitr). em aspectos particulares da invenção, as moléculas de anticorpo ligam-se especificamente a gitr humano e gitr de macaco cinomolgo. as moléculas de anticorpo anti-gitr da invenção foram desenvolvidas e otimizadas utilizando sequências de cdr derivadas de um anticorpo 6c8 anti-gitr murino. usos médicos das moléculas de anticorpo são divulgadas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1701351.7 | 2017-01-27 | ||
GBGB1701351.7A GB201701351D0 (en) | 2017-01-27 | 2017-01-27 | Binding agents |
GB1713296.0 | 2017-08-18 | ||
GBGB1713296.0A GB201713296D0 (en) | 2017-08-18 | 2017-08-18 | Binding agents |
PCT/GB2018/050239 WO2018138521A1 (en) | 2017-01-27 | 2018-01-26 | Binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019015453A2 true BR112019015453A2 (pt) | 2020-03-24 |
Family
ID=61132825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019015453-1A BR112019015453A2 (pt) | 2017-01-27 | 2018-01-26 | Agentes ligantes |
Country Status (13)
Country | Link |
---|---|
US (2) | US10457736B2 (pt) |
EP (1) | EP3574013A1 (pt) |
JP (1) | JP7169296B2 (pt) |
KR (1) | KR20190112299A (pt) |
CN (1) | CN110475787A (pt) |
AU (1) | AU2018213124A1 (pt) |
BR (1) | BR112019015453A2 (pt) |
CA (1) | CA3051797A1 (pt) |
IL (1) | IL268288A (pt) |
MX (1) | MX2019008905A (pt) |
RU (1) | RU2019125975A (pt) |
SG (1) | SG11201906963QA (pt) |
WO (1) | WO2018138521A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102123322B1 (ko) | 2019-11-01 | 2020-06-16 | 주식회사 미래에스엠 | 상판 오픈형 다용도 선반 |
KR20210132400A (ko) | 2020-04-27 | 2021-11-04 | 유미경 | 다용도 선반 |
TW202246334A (zh) * | 2021-02-02 | 2022-12-01 | 美商美國禮來大藥廠 | Gitr拮抗劑及其使用方法 |
JP2024517319A (ja) * | 2021-05-10 | 2024-04-19 | メディマブバイオ インコーポレイテッド | 抗gitr抗体およびその用途 |
WO2023060144A1 (en) * | 2021-10-05 | 2023-04-13 | Lanier Biotherapeutics | Monoclonal antibodies to il-25 and uses thereof |
WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2343320B1 (en) * | 2005-03-25 | 2017-10-25 | GITR, Inc. | Anti-gitr antibodies and uses thereof |
EP2473531A4 (en) * | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | ANTI-GITRANT ANTIBODIES |
TW201605896A (zh) * | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
PT3148579T (pt) * | 2014-05-28 | 2021-03-11 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-gitr e métodos da sua utilização |
DK3151921T3 (da) * | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
-
2018
- 2018-01-26 MX MX2019008905A patent/MX2019008905A/es unknown
- 2018-01-26 SG SG11201906963QA patent/SG11201906963QA/en unknown
- 2018-01-26 EP EP18702550.7A patent/EP3574013A1/en not_active Withdrawn
- 2018-01-26 JP JP2019561375A patent/JP7169296B2/ja active Active
- 2018-01-26 AU AU2018213124A patent/AU2018213124A1/en active Pending
- 2018-01-26 BR BR112019015453-1A patent/BR112019015453A2/pt unknown
- 2018-01-26 CN CN201880020490.8A patent/CN110475787A/zh active Pending
- 2018-01-26 KR KR1020197025095A patent/KR20190112299A/ko not_active Application Discontinuation
- 2018-01-26 WO PCT/GB2018/050239 patent/WO2018138521A1/en unknown
- 2018-01-26 RU RU2019125975A patent/RU2019125975A/ru unknown
- 2018-01-26 CA CA3051797A patent/CA3051797A1/en active Pending
- 2018-08-17 US US16/104,434 patent/US10457736B2/en active Active
-
2019
- 2019-05-29 US US16/424,676 patent/US20190375846A1/en not_active Abandoned
- 2019-07-28 IL IL268288A patent/IL268288A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110475787A (zh) | 2019-11-19 |
IL268288A (en) | 2019-09-26 |
MX2019008905A (es) | 2019-11-18 |
RU2019125975A3 (pt) | 2021-10-01 |
KR20190112299A (ko) | 2019-10-04 |
WO2018138521A1 (en) | 2018-08-02 |
JP7169296B2 (ja) | 2022-11-10 |
US20190010241A1 (en) | 2019-01-10 |
AU2018213124A1 (en) | 2019-09-12 |
EP3574013A1 (en) | 2019-12-04 |
RU2019125975A (ru) | 2021-03-01 |
CA3051797A1 (en) | 2018-08-02 |
SG11201906963QA (en) | 2019-08-27 |
JP2020505075A (ja) | 2020-02-20 |
US10457736B2 (en) | 2019-10-29 |
US20190375846A1 (en) | 2019-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019015453A2 (pt) | Agentes ligantes | |
BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
CO2020013392A2 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
PH12019501014A1 (en) | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof | |
CL2017003021A1 (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
EA201891992A1 (ru) | Химерные рецепторы и способы их применения | |
WO2016187220A3 (en) | Anti-ror1 antibodies | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
MX2018010445A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
BR112017019978A2 (pt) | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo | |
PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
NI201600162A (es) | Anticuerpos humanizados contra ceacam1 | |
NI201700012A (es) | Inhibidores de la proteina quinasa c y métodos de su uso | |
EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
MX2021007692A (es) | Proteinas de union anti-pd-1 y metodos de uso de las mismas. | |
MX2021007848A (es) | Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. | |
BR112018002436A2 (pt) | tratamento de combinação de usos de métodos destes | |
BR112019010128A2 (pt) | proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas | |
AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |